rethinkTHC Search
Menu
Study breakdown

CBD Raises Anandamide Levels But This Does Not Explain Its Blood Pressure-Lowering Effect

Randomized Controlled TrialStrong evidence
The takeaway

In a crossover RCT of 66 hypertensive patients, CBD raised anandamide levels but this did not correlate with blood pressure reduction, suggesting other mechanisms.

Cardiovascular and endocannabinoid researchers.

AEA rose 11.1 ng/mL but did not predict BP change

What the researchers found

CBD (225-450 mg/day, 5 weeks) increased AEA by 11.1 ng/mL (p=0.025). AEA change did not correlate with systolic BP change (r=-0.106, p=0.428). BMI, antihypertensives, and glucose predicted AEA increase; BP reduction did not. No 2-AG effect.

Why it matters

Dissociates CBD's endocannabinoid effects from its cardiovascular effects, redirecting mechanistic research.

The numbers in context

66 patients; AEA +11.1 ng/mL (p=0.025); BP correlation r=-0.106 (p=0.428); no 2-AG effect (p=0.478).

How the study worked

Sub-analysis of HYPER-H21-4 crossover RCT. 66 hypertensive patients. CBD vs. placebo for 5 weeks each. AEA and 2-AG measured.

What this study cannot tell us

Plasma may not reflect tissue changes. 5-week period. Only two endocannabinoids measured.

How to read the evidence

Well-designed crossover RCT. Plasma measurements may not capture full picture.

When this study was published

2025 sub-analysis of the landmark HYPER-H21-4 CBD-hypertension trial.

The bigger picture

CBD affects the endocannabinoid system and lowers blood pressure, but these may be independent effects.

Questions still open

  • What mechanism drives CBD blood pressure effects?
  • Do tissue endocannabinoid changes correlate with BP?

Common questions

Does CBD lower blood pressure via endocannabinoids?
CBD raised anandamide but this did not correlate with BP reduction, suggesting a different mechanism.
Does CBD affect endocannabinoid levels?
Yes, it raised anandamide but not 2-AG.

Read the original research

Can Endocannabinoids Explain CBD-Mediated Reduction in Blood Pressure? Insights from a Randomized, Placebo-Controlled, Crossover Trial.

Cannabis and cannabinoid research

Citation

Kumric, Marko; Dujic, Goran; Vrdoljak, Josip; Supe Domic, Daniela; Dujic, Zeljko; Bozic, Josko. (2025). Can Endocannabinoids Explain CBD-Mediated Reduction in Blood Pressure? Insights from a Randomized, Placebo-Controlled, Crossover Trial.. Cannabis and cannabinoid research. https://doi.org/10.1177/25785125251392773

Explore the wider topic